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A subgroup of patients treated with infliximab lose response to the treatment and one
reason for this is the development of anti-drug antibodies (ADA). If used optimally,
measuring drug and ADA level could lead to a more personalized and efficient treatment
regime, and enable identification of ADA-positive patients before the underlying disease
flares or allergic reactions occur. With the use of a drug-tolerant ADA assay which can
detect ADA irrespective of drug levels in the sample, we determined the impact of ADA on
treatment failure to infliximab. The aims of this study were to estimate the real-life optimal
serum infliximab (sIFX) level and set a clinical threshold value for a drug-tolerant ADA
assay. Trough levels of sIFX weremeasuredwith ELISA. Free ADAwasmeasuredwith two
drug-sensitive methods (ELISA and a bioassay) and one drug-tolerant method (PandA).
Two real-life cohorts treated with infliximab were included; a cross-sectional cohort
including patients with inflammatory rheumatic diseases (n = 270) and a prospective
cohort of rheumatoid arthritis (RA) patients (n = 73) followed for 1 year. Normal range of
sIFX was estimated from the prospective cohort and an arbitrary optimal drug level was
set to be between 1 and 6µg/mL. Using this range, optimal sIFX was found in only 60%
(163/270) of the patients in the cross-sectional cohort. These patients had significantly
better treatment response than those with a drug level under 1µg/mL, who had an ADA
frequency of 34% (19/56) using the drug-tolerant method. In the prospective cohort, the
drug-tolerant assay could identify 34% (53/155 samples) as ADA positive in samples
with sIFX level >0.2µg/mL. ADA were seldom detected in patients with >1µg/mL sIFX,
with three interesting exceptions. A clinically relevant ADA threshold was determined to
be >3 RECL as measured with the drug-tolerant assay. In a real-life setting, there was
a substantial number of patients with suboptimal drug levels and a proportion of these
had ADA. Both too low and too high drug levels correlated with worse disease, but for
different reasons. Adding a drug-tolerant assay enabled detection of ADA earlier and
regardless of drug level at time of sampling.
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INTRODUCTION
Infliximab is a chimeric monoclonal antibody (mAb) blocking
the effect of tumor necrosis factor alpha (TNF-α) which has
been widely used since 1999 for treatment of a number of
inflammatory rheumatic diseases including rheumatoid arthritis
(RA). TNF-α inhibitors (TNFi) were the first monoclonal
antibody therapy shown to significantly halt progression of these
diseases in clinical trials (1–3), and the treatment effect is even
more efficient in combination with other disease modifying
anti-rheumatic drugs (DMARDs) such as methotrexate (MTX)
(3). However, up to 40% of patients do not respond to TNFi
treatment according to the EULAR (European League Against
Rheumatism) response criteria (4–7). These patients can be
categorized into those who never achieve any response (primary
treatment failure), and those who lose response over time
(secondary treatment failure) (8). One cause for secondary
treatment failure is the development of anti-drug antibodies
(ADA) (9–12). ADA results in reduced availability of the drug
in the circulation (13) and therefore a lower effective dose (14–
16). There is an association between non-responders and low
serum trough infliximab (sIFX) levels (17) that is often due to
the development of ADA (18). Therefore, it is recommended
to start by first screening for the drug trough level and then
usually only those with low drug level are subsequently tested
for ADA.
The presence of ADA can lead to a subtherapeutic serum drug
level by either neutralization of the drug, leading to hampered
pharmacological activity, or through the sequestering of drug
resulting in increased clearance of immune complexes (IC) via
excretion through the kidneys (19, 20). ADA have also been
associated with adverse effects with an increased risk of infusion-
reactions, lupus, and vasculitis like events (21). Given that several
studies have shown that up to 44% of patients treated with TNFi
develop ADA, it is an important clinical issue to address. Routine
ADA testing would allow early identification of these patients
ensuring an efficient treatment regimen (3, 11, 22).
The prevalence of ADA to TNFi vary between studies,
which in part can be explained by differences in concomitant
medication use, timing of sampling in relation to the drug
administration, treatment duration, and type of assay used for
ADA detection (23–25). Standard immunoassays such as ELISA
are frequently used for ADA screening. However, disadvantages
of these assays include a low drug tolerance and ability to detect
only free ADA. When ADA bind to the drug to form immune
complexes, the antibodies become indiscernible using standard
laboratory techniques, leading to a false negative result (26).
One way to overcome the problem of drug interference is to
use a drug tolerant, precipitation, and acid dissociation (PandA)
assay. This procedure involves the addition of excess drug to the
sample followed by dissociation of ADA bound to the drug before
detection, making it possible to detect both free and bound ADA
in samples regardless of the level of drug in the serum (27).
At times, measurement of trough TNFi level and ADA are
used to monitor patients with chronic inflammatory disease
when the patient has no or little clinical improvement with
treatment (28). However, adjustments of dose and intervals are
often made without these types of supporting data. Despite
several suggestions, there is no consensus on which ADA
detection assay should be used, nor is the optimal drug trough
level known. Furthermore, the outcome of ADA and drug level
testing varies between different methods (25). In addition, there
is a lack of knowledge about how prevalent ADA are in patients
with detectable drug trough levels and at what level ADA have a
clinically relevant impact (29).
MATERIALS AND METHODS
Patient Cohorts
This study included two cohorts; With patients from (1) a
cross-sectional cohort from the Karolinska University Hospital,
Stockholm (n = 270) and (2) a prospective cohort from the
Sahlgrenska University Hospital, Gothenburg (n= 73), described
in Table 1. In the cross-sectional study, all patients treated with
infliximab in the rheumatology clinic between January 2017 to
December 2017 were recruited (n = 270). Several samples were
collected per patient at trough prior to an infusion. In the cross-
sectional cohort, 43% (n = 115) of the included patients had
RA, 44% (n = 118) had other type of inflammatory arthritis
(spondylarthritis, ankylosing spondylitis, psoriatic arthritis,
reactive arthritis, enteropathic arthritis, or undifferentiated)
and 14% (n = 37) had other systemic inflammatory diseases.
All patients (except four) in the cross-sectional cohort were
switched to infliximab biosimilar InflectraTM in 2017. A total of
63% (169/270) of the patients were concomitantly treated with
conventional synthetic disease-modifying anti-rheumatic drug
(csDMARD) (156 with methotrexate; 6 with sulfasalazine; 4 with
azathioprine; 3 with leflunomide).
In the prospective study, all RA patients initiated on infliximab
from the Sahlgrenska University Hospital between 2017 and
2019 were included. Patients in the prospective cohort (n =
73) were included prior to initiation of infliximab treatment
and followed for up to 1 year. All patients but one (previously
treated with infliximab 2011-2012 and golimumab December
2016 to December 2017), were naïve to infliximab treatment
at baseline. The majority of patients were concurrently treated
with methotrexate, either alone (n = 52) or in a combination
with salazopyrin (n = 5), plaquenil (n = 2) or prednisolone
(n = 9) at the initiation of infliximab therapy. Four patients
received concomitant salazopyrin only and one patient was
treated with infliximab monotherapy. The patients treated at
Sahlgrenska received a dosing schedule as follows; baseline,
the second dose was received after 2 weeks, the third dose
after 1 month, and thereafter, every 8 weeks. For this cohorts,
serum samples were collected at baseline and trough prior
to each infusion. The infliximab dosing regimen for this
cohort was 200mg intravenous infusion administered every 8
weeks. Patients that failed to respond were given either an
increased dose and/or shortened treatment intervals or were
switched to another treatment. This decision was made by the
treating physician.
All patients signed informed consent to participate in this
study, which was approved by Stockholm Regional Ethical
Committee (2013/1034-31/3) and Gothenburg Regional Ethical
Committee (1028-15, 2016-02-12).
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TABLE 1 | Baseline patient characteristics in prospective and cross-sectional cohorts.
Characteristic Cross-sectional cohort Prospective cohort
RA Spondyloarthropathies Other systemic inflammatory
diseases
RA
n (%)* 115 (42.6) 118 (43.7) 37 (13.7) 73 (100)
Age (median, min-max) 65 (31–83) 51 (20–80) 45 (20–84) 52 (18–89)
Female (n,%) 90 (78) 40 (34) 24 (65) 58 (79)
Concomitant DMARD (n,%) 91 (79) 54 (46) 24 (65) 72 (98)
MTX (n,%) 86 (75) 49 (42) 21 (57) 68 (93)
Other DMARD (n,%) 5 (4) 5 (4) 3 (8) 4 (5)
lnfliximab dose (median mg/IV, IQR) 210 (200–300) 250 (200–300) 260 (200–300) 200 (150–200)
Duration of treatment (median, IQR) 9 (4–18) 6 (2–11) 4 (1.5–8) n.d.
Current smokers (n,%) 9 (8) 13 (11) 3 (8) 9 (12.5)
Ever smokers (n,%) 61(53) 63 (53) 28 (54) 40 (56)
Never smokers (n,%) 53 (46) 53 (45) 17 (46) 32 (44)
Disease duration (median, IQR) 17 (11–23.5) 14 (6.75–24) 11 (4.5–20) 1.5 (0.5–10.55)
Seropositive (n,%) 83 (72) n.d. n.d. 53 (75)
Seronegative (n,%) 32 (28) n.d. n.d. 17 (24)
CRP (median mg/L, IQR) 1 (1–4) 1 (1–4) 2 (1–4.5) 4 (1–9.75)
Patient global health assessment (median, IQR) 29 (10–49) 26 (11–52) 42 (11–65) 46 (1–86)
Pain (median VAS, IQR) 24.5 (10.75–46.25) 27 (10–49) 36 (7–66) 47 (2–95)
HAQ score (median, IQR) 0.5 (0.13–1.13) 0.25 (0–1) 0.4 (0.1–1.28) 0.89 (0–2.75)
DAS28 (median, IQR) 3.13 (2.03–4.65) n.d. n.d. 3.6 (0.53–7.57)
RA, rheumatoid arthritis; n, number; IQR, interquartile range; MTX, methotrexate; DMARD, disease-modifying antirheumatic drug; CCP, citrullinated protein; RF, rheumatoid factor;
seropositive is defined as RF positive, CCR positive or both; seronegative is defined as RF and CCP negative; CRP, C-reative protein, VAS, visual analog scale; HAQ, health assessment
questionnaire; DAS28, disease activity score 28; n.d, no data. *% of the total patients within the cohort.
Measurement of Clinical Data
Routine clinical examinations of patients were performed by
treating rheumatologists at regular intervals according to local
clinical practice, the Disease Activity Score in 28 joints (DAS28)
was calculated and data registered in the Swedish Rheumatology
Quality Register (SRQ). The first visit to evaluate the treatment
response usually occurred 3–4 months after initiation of
infliximab treatment. Clinical data including disease duration,
rheumatoid factor (RF)/cyclic citrullinated peptide (CCP) status,
smoking habits, and concomitant csDMARD treatment was
retrieved from SRQ and patients’ medical records. Seropositivity
was defined as being CCP and/or RF positive and seronegativity
was defined as being CCP and RF negative.
Assessment of Disease Activity
The composite disease activity score (DAS28) was used. The
DAS28 score takes into account the number of swollen and
tender in a 28-joint count, the erythrocyte sedimentation rate
(ESR) or C-reactive protein (CRP) and patient’s assessment of
global health on a visual analog scale (VAS-GH). Based on
this score, patients were classified into the following categories:
remission DAS28 <2.6, low disease activity DAS28 2.6–3.2,
moderate disease activity 3.2–5.1, and high disease activity
>5.1. The change in a patient’s score over time, is expressed
as delta (1) DAS28, was calculated by subtracting baseline
DAS28 score from the respective final post-treatment score.
Using the 1DAS28, patients were categorized as either good,
moderate, or non-responders to infliximab treatment according
to the European League Against Rheumatism (EULAR) response
criteria as previously described (30). In short, good responders
are defined as those with a 1DAS28 >1.2 and a current DAS28
≤ 3.2; moderate responders by a 1DAS28 >1.2 and a current
DAS28 >3.2 or a 1DAS28 between 0.6–1.2 and a current DAS28
≤ 5.1; non-responders were defined as those with a 1DAS28
<0.6 or 1DAS28 between 0.6–1.2 and a current DAS28 score
>5.1. For the cross-sectional cohort, the DAS28 used for analyses
were assessed within 3 months from the infliximab trough drug
level measurement which was used for the study analyses.
ELISA for Detection of Infliximab Serum
Trough Levels
Infliximab trough level was measured in patient sera using
an in-house developed and validated ELISA which is used in
clinical routine, as previously described (28). Briefly, microtiter
plates (Nunc Maxisorp F 96, Thermo-Fisher Scientific, Roskilde,
Denmark) were coated with 50 µL per well of recombinant
human TNF-α (200 ng/mL) (R&D Systems, Minneapolis, MN,
USA) in 0.05M sodium carbonate buffer pH 9.6. The plates
were put on a shaker at room temperature (RT) for 2 h before
being incubation overnight in +4◦C. The plates were then
washed three times with phosphate buffered saline (PBS) plus
0.05% pH Tween 20 and blocked with PBS + 1% bovine serum
albumin (BSA) (Sigma, St. Louis, MO, USA) and 0.05% Tween
20 (blocking buffer) for 1 h at RT. After washing, standard
dilutions (0.40–100 ng/mL) of infliximab (Schering Plough,
Kenilworth, NJ, USA), internal controls (defined IFX-spiked
sera), and patient samples, diluted 1/500 in blocking buffer, in
duplicates were added to the plate. Plates were incubated on
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a shaker at RT for 1 h and washed four times before addition
of alkaline phosphatase (ALP)-conjugated goat anti-human IgG
(Fc-specific) (Sigma) diluted 1/10 000 in a blocking buffer. The
plates were again incubated on a shaker at RT for 1 h and washed
four times. The substrate (p-nitrophenyl-phosphate, 5 mg/mL in
1M diethanolamine with 0.5mM Mg, pH 9.8) was added and
color development was monitored at 405 nm. The concentration
of samples and controls was calculated from the standard curve
where the lower and upper limits of quantification were 0.2 and
50µg/mL, respectively (compensated for serum dilution 1/500).
Inhibition ELISA for Detection of
Antibodies to Infliximab
ADA to infliximab was detected using an in-house developed
and validated ELISA, which is based on the inhibition of labeled
infliximab binding to TNF-coated ELISA plates, as previously
described (28). Alkaline phosphatase (ALP) was coupled to
infliximab using the Lightning-Link kit (Innova Biosciences Ltd.,
Cambridge, UK). The ELISA plates were coated with TNF-α, as
described for the infliximab ELISA above. A standard consisting
of goat anti-human IgG (Jackson Immuno Research) at a final
concentration of 1µg/mL was used. Patient sera were analyzed at
final dilutions of 1:10 and 1:100. The standard defined control
sera and patient samples were incubated with ALP-conjugated
infliximab for 1 h at RT. After an additional wash of the TNF-
coated plate, aliquots of standard, controls and patient samples
were transferred to the plate in duplicates. After incubation on
a shaker for 1 h at RT, the plate was washed and substrate (p-
nitrophenyl-phosphate, 5 mg/mL in 1M diethanolamine with
0.5mM Mg, pH 9.8) was added, and color development was
monitored at 405 nm. The results were transformed to percentage
inhibition by normalization of the OD of the samples to that of
the standard (100% inhibition) using the formula (OD blank –
OD sample)/(OD blank – OD standard) x 100. The lower limit
of detection was set to the value plus two standard deviations
obtained from measurements of normal control sera. Due to
free infliximab interference with the assay, ADA could only
be detected in the absence of the drug. ADA analysis was
therefore limited to patient samples where serum infliximab was
undetectable (<0.2 µg/mL).
ADA Detection With the Precipitation and
Acid Dissociation (PandA) Method
Presence of ADA to TNF-α inhibitors was assessed using the
PandA method described by Zoghbi et al. (27) on the Meso Scale
Discovery R© (MSD) platform. The PandA assay has demonstrated
high sensitivity to detect ADA in the presence of a high
concentration of drug (drug tolerant). The assay is therefore,
more suitable for immunogenicity assessment of patient samples
that contain detectable levels of infliximab which interfere with
the detection limit of ADA in other immunoassays. Serum
from 40 healthy donors (Stockholm blood center, Sweden) was
collected to prepare a pool of normal healthy sera (NHS) to be
used as negative control (NC) in the PandA assay. Informed
written consent was given by all the donors. Human anti-IFX
(clone HCA233, BIO-RAD) was prepared in NHS to be used
as a high positive control (6µg/mL) and low positive control
(1µg/mL). The PandA assay was validated in-house before
analysis of study samples. A plate specific, or floating, cut-point
was applied to allow a 5% false positive rate in the screening
assay. For each plate, the cut-point is calculated by multiplying
the NC value of the plate with a normalization factor (NF), which
is the average of all NC values obtained from six assay plates in
the validation process (three operators running one plate each
over two days). To resolve the problem of interference of soluble
infliximab in the sera, 25 µL of patient samples were diluted 1:2
in 2% bovine serum albumin (BSA, Sigma) in PBS containing
10µg/mL infliximab (Remicade R©) in a polypropylene V-bottom
plate (Thermo Scientific) in duplicate wells. ADA present in the
sera were then able to bind to the excess soluble infliximab,
forming immune complexes during a 1 h incubation at RT at
450 rpm. Formed immune complexes were then precipitated
by addition of 50 µL 6% polyethylene glycol (PEG, Aldrich)
solution to each sample (3% PEG in the plate) during overnight
incubation of the plate at 4◦C. The following day, the plate
was centrifuged at 3,724 x g for 30min to precipitate immune
complexes into a pellet. After the supernatant was discarded,
the pellets were re-suspended with a 3% PEG solution and the
plate centrifuged at 3,724 g for 20min. This step was repeated
once more. After the final centrifugation step, pellets were re-
suspended with 250 µL 0.25M acetic acid, pH 3.0, to get
a minimal required dilution of 1/10. Samples were thereafter
transferred to a high binding carbon plate (MSD) by adding
50 µL of each sample in duplicates. The plate was thereafter
incubated for 1 h at RT at 450 rpm. Following incubation, the
plate was washed once with 300 µL 1x wash buffer (1xPBS, 0.1%
Tween, pH 7.4) and blocked with 300 µL casein in PBS pH 7.4
(Thermo Scientific) for 1 h at RT at 450 rpm. After additional
washing, 50 µL of the master mix containing 0.5µg/mL of
Sulfo-Tag conjugated infliximab (labeling ratio of 20:1 between
Sulfo-Tag and IFX) (MSD GOLDTM) in 2% BSA in PBS was
added to the samples and incubated for 1 h at RT at 450 rpm.
After the final incubation, the plate was washed once and within
5min of adding 150 µL read buffer T (2x) (MSD) the plate
was read on MESO Quickplex SQ 120 (MSD). By electrical
discharge, the electrons are excited and a stable light signal
is generated. This electrochemiluminescence (ECL) signal is
proportional to the amount of ADA in each serum sample. A
signal to background ratio was calculated by dividing the average
ECL signal from an individual sample by the average ECL signal
of the negative control (NHS) and expressed as relative ECL
(RECL). The coefficient of variation value of ≤25% was accepted
as the maximum variation between duplicates.
Neutralizing Anti-drug Antibody Analysis
The neutralizing capacity of the ADA were measured using
iLiteTM infliximab NAb bioassay (Biomonitor) in 35 serum
samples from 29 patients in the cross-sectional study, who
previously detected ADA-positive by the ELISA method. The
protocol was carried out according to the manufacturers’
instructions. In short, the assay uses division-arrested TNF-α
sensitive cells to measure TNF-α bioactivity. Transcription of
the luciferase gene occurs when TNF-α binds to the TNF-α
Frontiers in Immunology | www.frontiersin.org 4 July 2020 | Volume 11 | Article 1365
Kharlamova et al. Infliximab ADA With PandA
receptor and the luciferase activity is inversely proportional to the
amount of infliximab present in the sample. Luciferase activity
was measured using GloMax Luminometer (Promega) and the
antibody neutralizing activity was normalized to Renilla (31). The
assay’s drug tolerance is 0.65 µg/mL.
Statistical Analysis
To compare continuous variables, Mann-Whitney U-test for
independent groups was used. All reported p-values were two
tailed, and a p-value of < 0.05 was considered statistically
significant. Correlation analysis was performed using Spearman’s
rank correlation. Receiver operating characteristic (ROC) curves
were constructed to assess the cut-off of drug level- and
ADA threshold values were based on EULAR response criteria
(good responders vs. non-responders). The cut-off points were
calculated on the basis of the best trade-off values between
sensitivity and specificity. Statistical calculations were performed
using Prism software (GraphPad Inc. version 8).
RESULTS
Patient Characteristics
Baseline patient characteristics of the infliximab-treated cohorts
are summarized inTable 1. Patients in the prospective cohort had
a median disease duration of 1.5 years (IQR 0.5–11) at baseline.
In contrast, patients in the cross-sectional cohort had a wide-
ranging disease and treatment duration at the time of baseline
sampling. The study time points of sample collection for the
prospective cohort and diagnoses for the cross-sectional cohort
are illustrated in Figures S1, S2.
Serum Infliximab Levels
The sIFX values in the prospective study were found to be higher
at the beginning of the treatment period when the intervals were
2 and 4 weeks between infusions. It then reached a stable range
with amean of 1.8µg/mL [standard deviation (SD) of 2.0µg/mL]
from week 14 when infusions were 8 weeks apart (Figure 1).
To determine an optimal sIFX level defined as the range of
trough levels that had the sensitivity and specificity to predict
good EULAR response, Receiver Operating Characteristic (ROC)
curves where done for both the cross-sectional cohort and the
prospective cohort (Figure 2). On the analysis, the therapeutic
ranges were distributed in a U-shaped curve at the lower and
upper ends. Therefore, each end were analyzed separately. Firstly,
the lower end was determined on all samples with a sIFX under
3.8µg/mL, corresponding to the mean+ SD for the stable range.
With an area under the curve (AUC) of 0.8, both cohorts gave
a predictive optimal value of 0.95µg/mL indicating this is the
lowest sIFX level which you can expect the treatment to have
good effect. For ROC analysis, the EULAR response was used as
the clinical outcome and for the prospective cohort both EULAR
response and remission status were used.
Using the previously suggested lower limit for optimal
therapeutic effect of 1µg/mL sIFX (32) and the data from the
ROC analyses (taking into account the interassay variations), an
approximate lower end of an optimal range was set to 1µg/mL.
Secondly, an upper end for the optimal range was estimated
FIGURE 1 | Trough serum infliximab levels (sIFX) for all RA patients in the
prospective cohort and variation over time. Total number of weeks on
treatment is shown on the x-axis. The levels are presented as median (bar) and
interquartile range (red). Number of individuals at each time point is illustrated
in Figure S1A.
FIGURE 2 | Receiver operating characteristic curve (ROC) for setting optimal
cut-point of trough sIFX separating good from non-responders (based on
EULAR criteria). Black line with quadrates shows cross-sectional cohort and
gray dotted line represents prospective cohort. The levels of trough sIFX of the
prospective cohort were taken at 14 weeks after treatment initiation. Area
under the ROC curve (AUC) was 0.81 and the cut off level was 0.95 for both
cohorts.
using the mean + 2xSD of the stable sIFX period (from week
14 onward) in the prospective cohort, which was found to be
6µg/mL sIFX in trough. This is in line with what has been shown
previously for other TNFi (28, 33).
Using this range (1–6µg/mL) as optimal, only 55% of the
samples (n= 169) from RA patients in the cross-sectional cohort
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FIGURE 3 | Levels of trough serum infliximab (sIFX) in RA patients in the
cross-sectional cohort. Samples divided based on suggested optimal levels
(1–6µg/mL) of trough sIFX. The levels are presented as median (red line) and
interquartile range (whiskers).
had an optimal sIFX, 37% had lower than 1µg/mL, and 8% had
higher than 6µg/mL (Figure 3). The proportions were similar
for the other non-RA infliximab treated patients in this cohort,
where 65% of the samples (n = 273) had an optimal sIFX, 24%
had lower than 1µg/mL, and 11% had sIFX higher than 6µg/mL.
In the prospective study, only 54% of all samples (n = 159)
collected from 65 patients from week 14 onwards had sIFX levels
within the suggested optimal range, 42% of the samples had sIFX
levels <1µg/mL and 4% had a level higher than 6µg/mL.
As a comparison, five samples which had been mistakenly
collected directly after the infusion, were found to have a mean
sIFX level of 46µg/mL (median 48µg/mL, range 42–52µg/mL).
These were not included in the analyses.
Clinical Relevance of Serum Infliximab
Levels
Clinical variables were used to analyse the correlation between
sIFX and treatment response in the cross-sectional cohort. For
RA patients in the cross-sectional cohort, if a DAS28 score
was available within 5 months of the time of sampling (n =
34) this was also used to evaluate the correlation. Using the
DAS28, patients were then classified as previously described
using the EULAR response with good, moderate or non-response
categories (30). The sIFX levels were significantly lower in
the non-responders group compared to the good responders
(Figure 4). In the moderate responder group, there is one outlier
case with a high sIFX level (15µg/mL), indicating that also a
high drug level might be associated with less optimal therapeutic
response. The cross-sectional cohorts’ sIFX levels were divided
into the categories of under 1, 1–6, and above 6µg/mL and
analyzed for correlation with clinical variables, including DAS28
(n = 34) (Figure 5) and delta-DAS28 (n = 34) (Figure S3) for
the RA patients. Variables on patient global assessment (PGA)
(Figure S4), patient pain assessment (VAS) (Figure 6), CRP
(Figure 7), and ESR (Figure 8), were analyzed for all infliximab
treated patients in the cross-sectional cohort. Clinical variables
were significantly worse in patients with a sIFX trough level
below 1µg/mL compared with those with a drug level between
1 and 6µg/mL (DAS28 (p = 0.01), PGA (p = 0.01), CRP (p =
0.002), and ESR (p= 0.004).
Only a few patients had sIFX >6µg/mL (n = 8, of which 3
were RA patients) and both CRP (p= 0.03) and ESR (p= 0.007)
were significantly worse in these compared with those with a
drug level between 1 and 6µg/mL. One possible reason for a very
high sIFX level could be the presence of more severe disease at
treatment initiation and therefore, dosing intervals are shortened
or doses increased in attempt to manage the patients’ symptoms.
Patients from the cross-sectional cohort with sIFX>6µg/mL did
indeed have both a higher DAS28 and a higher treatment dose
(Figure S5).
In the prospective cohort the correlation between EULAR
response and sIFX levels varied between time points, but
collectively, the non-responders had a significantly lower sIFX
level than the good responders (Figure S6).
Proportion of Patients With Free ADA
Given that the drug sensitive ELISA method only reliably detects
free ADA, not bound in immune complexes, it is recommended
that only samples with sIFX below the drug sensitivity of the assay
(<0.2µg/mL) are tested. Of the 73 patients in the prospective
cohort, 44 (60%) had a sIFX <0.2µg/mL at some time point
allowing the sample to be tested for ADAwith ELISA. Of these 44,
86% (n= 38), or 59% of the whole cohort, were positive for ADA.
Compared to this early RA cohort, a lower proportion of the
cross-sectional cohort, or 14% (37 of 270 patients) of the whole
cohort were found to be ADA positive in samples with sIFX levels
<0.2µg/mL (42 of 270), probably reflecting a selection bias of
patients who continue on infliximab.
ADA in Samples With Detectable sIFX
Level Using PandA
With the drug-tolerant PandA method, ADA can be detected
regardless of drug level, and therefore we could determine the
frequency of ADA in samples with sIFX >0.2µg/mL. A selection
of samples from the cross-sectional cohort with sIFX levels
ranging 0.2–7µg/mLwere analyzed with PandA (Figure 9). Only
a 26 additional ADA positive samples were identified with this
method and for the cross-sectional cohort all had a sIFX levels
under 1µg/mL. Similar results were found in the prospective
cohort, with three interesting exceptions described more in detail
below (Figure 10). A significant reverse correlation was found
between ADA and sIFX levels in both cohorts (r2 = −0.4, p <
0.0001 for cross-sectional cohort and r2 = −0.7, p < 0.0001 for
the prospective cohort).
In the prospective cohort, the kinetics of total (free and
IC bound) ADA development was determined using the drug-
tolerant PandA assay. ADA was found to develop early after
treatment initiation and the first positive samples could already
be identified prior to the 2nd infusion at week 2. The incidence
of ADA increased until the 6th infusion at week 30, but cases
with their first positive sample were detected up until the 9th
infusion at week 54. The cumulative prevalence of ADA increased
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FIGURE 4 | EULAR response in relation to sIFX levels for the subgroup of RA patients in the cross-sectional cohort (n = 34). The sIFX levels were significantly lower in
the non-responders group compared to the good responders. Percentage of patients in each EULAR group given in brackets on x axis. The levels are presented as
median (bar) and interquartile range (whiskers).
up to the 6th infusion at week 30 before beginning to decrease
(Figure S7).
ADA Results From ELISA Compared to
PandA
Of the 108 selected prospective samples tested on both PandA
and ELISA methods, there was a 72% (n = 78) agreement
between assay results [68% (n = 74) confirmed positive and
4% (n = 4) confirmed negative]. However, there were some
discrepancies between assays, with 20% (n = 22) positive in
PandA but negative with ELISA, and 7% (n = 8) positive with
ELISA but negative with PandA.
Of the five patients with sIFX levels <0.2µg/mL that were
negative for ADA with ELISA, one was confirmed positive
with PandA.
ADA in Complex With Drug Can Be
Detected Earlier Than Free ADA
In the prospective cohort, 45 patients from whom we could
retrieve samples which were taken prior of being identified as
ADA positive with ELISA, were tested for ADA with PandA.
Of these, 17 patients (38%) were found to be ADA positive at
an earlier time point. These were on average detected 20 weeks
(median 16, range 4–41 weeks) before the sIFX levels were low
enough for detection of ADA with ELISA.
Three unique cases were identified which were found to be
ADA positive despite very high sIFX and therefore serial samples
from these cases were analyzed (Table 2). The first case was newly
diagnosed and was trialled onmethotrexate for 2 months without
effect before initiating the first infliximab infusion. This patient
was highly ADA positive (PandA RECL = 10) already at the
2nd infusion, just 2 weeks after treatment initiation. As the sIFX
was 5.8µg/mL, this patient would not have been tested for ADA
with ELISA until the next infusion at week 6, when the drug
level was <0.2 µg/mL. In this sample the ELISA test could then
confirm ADA positivity. An infusion reaction was noted at the
third infusion, which worsened despite precautions taken before
the 4th infusion. The patient discontinued treatment after the 4th
infusion due to infusion reactions and lack of treatment effect.
The patient was switched to rituximab treatment.
The second case was also newly diagnosed and was treated
with prednisolone and methotrexate for 6 months prior to
their first infliximab infusion. This patient was also highly ADA
positive (PandA RECL = 75) already at the 2nd infusion (week
2) and with a sIFX level of 12.2µg/mL. This patient was tested
for ADA with ELISA in a subsequent sample taken at the
6th infusion, 28 weeks after treatment initiation with a serum
infliximab of 0.8 µg/mL. At this point, the patient was found
to be ADA negative with ELISA and still positive with PandA
(RECL = 22). At the 7th infusion, the sIFX level had decreased
to 0.2µg/mL and at this time point, the patient was first detected
as ADA positive using the ELISA. This was 37 weeks after the first
ADA positive detected using the PandAmethod. At this time, the
patient experienced good effect of the treatment with a DAS28
of 2.8. A year later the treatment effect declined and the interval
was shortened to 6 weeks without effect. The patient was then
switched to etanercept.
The third case was newly diagnosed with low disease
activity (DAS28 at treatment initiation 3.02) and was initially
managed with intra-articular cortisone injections. Methotrexate
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FIGURE 5 | Bar plot of DAS28 levels in a subgroup of the RA patients in the
cross-sectional cohort (n = 34). Patients with RA were divided into three
groups based on trough sIFX: under 1, 1–6, and above 6µg/mL. DAS28 was
significantly worse in patients with a sIFX trough level below 1µg/mL
compared with those with a drug level between 1 and 6µg/mL. Dotted line
depicts DAS28 of 3.2 and indicates low disease activity bellow this line. The
trough sIFX levels presented as median (bars) and interquartile range
(whiskers). Colored dots represent 3 RA patients who had sIFX >6µg/mL.
was initially used but terminated due to a herpes zoster infection,
which was managed with vaccination and anti-viral therapy.
Infliximab treatment was started 2 years later, initially with good
effect. This patient was ADA negative in PandA (RECL = 1)
prior to the 2nd infusion, but highly positive prior to the 3rd
infusion (RECL = 15) when the sIFX was still high (3.5µg/mL).
In the sample taken prior to the 4th infusion, sIFX was 0.1µg/mL
and ADA positive with ELISA, and PandA however, the PandA
positive level had dropped to 5 RECL. With the subsequent
infusions the ADA increased to very high levels (RECL = 394
prior to the 8th infusion). An infusion reaction was documented
after the 5th infusion and fevers after infusion 6 and 7, followed
by facial skin reactions after infusion 8. The infusion reaction
worsened after the 9th infusion and the patient was then shifted
to adalimumab.
Clinical Threshold Value for ADA
When ADA positivity measured by PandA was stratified by
patients’ EULAR response categories good, moderate or non-
responder, a notable difference between the proportion of ADA
positive patients was observed between groups (Figure S8).
However, this was less clear over time (Figure S9). Overall, a
higher mean ADA value was found in the group with EULAR
non-responders (15.7 RECL), whereas 79% of patients in the
moderate and good EULAR response groups had a ADA result of
<3 RECL. This suggests that there is a clinical threshold value for
ADA of around 3 RECL, using thismethod. A ROC analysis using
FIGURE 6 | Bar plot of the levels of patients’ pain assessment (visual analog
scale 100mm; VAS) in all patients (with available data) treated with infliximab in
the cross-sectional cohort. Patients were divided into three groups based on
trough sIFX: under 1, 1–6, and above 6µg/mL. VAS was significantly higher in
patients with a sIFX trough level below 1µg/mL compared with those with a
drug level between 1 and 6µg/mL. The trough sIFX levels presented as
median (bars) and interquartile range (whiskers). Colored dots represent 3 RA
patients.
the RECL values from prior to the 4th infusion (week 14) and
the overall EULAR outcome (good and non-responders) of the
patients in the prospective study, confirmed a clinical threshold
value of 3.25 (AUC 0.9, p= 0.028) (Figure S10). When remission
outcomes were also used, the clinical threshold value was 1.48
(AUC 1.0, p= 0.01) (Figure S10).
ADA Correlation to Seropositivity and to
Smoking Status in RA Patients
In the prospective cohort, the level of ADA, as measured with
PandA method, had a positive correlation with serological status
of the patients (Figure S11). Over time, the most prominent
correlation was noted prior to infusion 8 (Figure S12). This effect
was due to the RF and when analyzed separately, patients who
were RF positive had significantly higher ADA RECL values
(Figure 11), seen also over time (Figure S13).
The smoking status of the patients was available for 54% of
patients, and a highly significant correlation in ADA levels was
seen between ever smokers (n= 84) and never smokers (n= 63)
(p-value= 0.0001) (Figure 12), a pattern that could also be noted
over time (Figure S14).
ADA to Infliximab Had Neutralizing
Capacity
In the cross-sectional cohort, serum samples from 29 patients
who tested positive for free ADA with the ELISA, were further
tested for neutralizing capacity using the iLite bioassay. Nineteen
of those patients (66%) tested positive for neutralizing ADA
Frontiers in Immunology | www.frontiersin.org 8 July 2020 | Volume 11 | Article 1365
Kharlamova et al. Infliximab ADA With PandA
FIGURE 7 | Bar plot of the levels of C-Reactive Protein (CRP) in all patients
(with available data) treated with infliximab in the cross-sectional cohort.
Patients were divided into three groups based on trough sIFX: under 1, 1–6,
and above 6µg/mL. CRP was significantly higher in patients with a sIFX
trough level below 1 and above 6µg/mL compared with those with an optimal
drug level. The trough sIFX levels presented as median (bars) and interquartile
range (whiskers). Colored dots represent 3 RA patients.
against infliximab. There was a strong correlation between assays
(r= 0.9, p< 0.001), particularly in those with RECL values above
the clinical threshold value (RECL > 3) (Figure S15).
Transient and Persistent ADA
In the prospective cohort, 39 patients were identified as ADA
positive with PandA method, and 29 of these had one or more
samples taken after they first were determined to be positive.
Therefore, they could be assigned as transient or persistent
positive. The majority of these were persistent positive (n = 22,
56%) and had a higher peak RECL (median of 5.1, IQR 2.2–
14.4) compared to the transient positive (n = 7, 18%) with a
peak RECL value of 1.2 (IQR 1.2–1.3). Notably these groups
were on either side of the suggested clinical threshold value for
ADA (1.48–3.26).
Therapeutic Drug Monitoring Test
Algorithm
Based on the results of this study, we suggest a treatment
algorithm for interpreting the results of the sIFX and ADA
tests (Figure 13). We propose as a first step, measuring the
sIFX level, which allows patients to be allocated to one of
four groups. Group 1 and Group 2 consists of patients with
either undetectable infliximab levels (<0.2µg/mL) or low sub-
therapeutic sIFX trough levels (<1µg/mL) and should therefore
be tested for ADA using an ELISA or drug-tolerant assay
(PandA), respectively. Not all patients with low sIFX levels
FIGURE 8 | Bar plot of the levels erythrocyte sedimentation rate (ESR) in all
patients (with available data) treated with infliximab in the cross-sectional
cohort. Patients were divided into three groups based on trough sIFX: under 1,
1–6, and above 6µg/mL. ESR was significantly higher in patients with a
suboptimal sIFX trough level (below 1 and above 6µg/mL) compared with
those with a drug level between 1 and 6µg/mL. The trough sIFX levels
presented as median (bars) and interquartile range (whiskers). Colored dots
represent 3 RA patients.
can be explained by ADA and an increased infliximab dose
could therefore be considered for those found to be ADA
negative at this step. For patients found to be ADA positive,
other treatment options should be considered depending on
the ADA level and its relationship with the clinical threshold
value. If the sample is ADA positive with a RECL value >3,
the patient should be switched to another treatment due to the
likely treatment inhibition and loss of effect owing to ADA.
If the ADA level <3 RECL, there may still be an effect of the
treatment despite the presence of ADA and it is possible the
patient may only be transiently positive. In these cases, one could
continue treatment, but consider repeat testing for ADA again in
the coming months to monitor for ADA persistence using the
quantitative PandA method. Group 3 includes patients whose
sIFX falls within the optimal sIFX range. Therefore, no action
is needed if the disease is in remission or demonstrating an
acceptable response to treatment. If the disease is not in remission
despite sIFX being within optimal range, a drug with another
mode of action might be needed. Group 4 includes patients with
a higher than normal trough sIFX level (>6µg/mL). This might
reflect a situation where the drug is not consumed as expected.
Therefore, lowering the dose should be considered if the patient is
responding well to infliximab. However, treatment options with
another mode of action could also be considered for patients
who have not responded well and have disease activity. The three
exceptional cases with early high ADA titers were excluded from
this algorithm and patients such as these, will only be detected
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FIGURE 9 | Correlation between ADA reactivity (in relative ECL; RECL) and trough sIFX levels in cross-sectional cohort. A significant reverse correlation was found
between ADA and sIFX levels with r2 of −0.4 and p < 0.0001. ADA reactivity was detected with PandA assay. Dotted line separates samples positive for ADA.
FIGURE 10 | Correlation between ADA reactivity and trough sIFX levels in
prospective cohort. A significant reverse correlation was found between ADA
and sIFX levels with r2 of −0.7 and p < 0.0001. ADA reactivity was detected
with PandA assay. Dotted line separates samples positive for ADA. Arrows
pointed out at three exceptional cases with a high levels of trough sIFX and
ADA simultaneously.
if a first tier of the ADA testing is with the PandA method prior
to the second infusion. As these patients later developed infusion
reactions, one might want to consider changing to an alternative
treatment already at this early time point.
TABLE 2 | Three unique cases which were found to be ADA positive despite very
high sIFX.
Infusion of Infliximab
2nd 3rd 4th 5th 6th 7th 8th 9th
Case #1
PandA, RECL 10 16 31 n/a n/a n/a n/a n/a
sIFX 5.8 <0.2 <0.2 n/a n/a n/a n/a n/a
ELISA n/a pos pos n/a n/a n/a n/a n/a
Case #2
PandA, RECL 75 48 39 39 22 18 12 12
sIFX 12.2 8.6 2.6 2.2 0.8 0.2 0.1 0.1
ELISA n/a n/a n/a n/a neg pos pos pos
Case #3
PandA, RECL 1 15 5 23 267 355 394 n/a
sIFX 15.7 3.5 0.05 0.0 0.0 0.0 0.0 n/a
ELISA n/a n/a pos pos pos pos pos n/a
Serial samples from these cases were analyzed. ADA was measured by Elisa and PandA
assays. In all of these cases ADA have been detected with PandA already at the 2nd or
3rd infusion. Bold indicates positive ADA values.
DISCUSSION
Unwanted immunogenicity is a growing challenge for
management of patients treated with biopharmaceuticals. To
be able to provide the highest quality of care, the consequences
of ADA on safety and treatment efficacy have to be addressed.
However, the benefit of integrating assessment of drug level and
ADA in clinical practice has been questioned for several reasons,
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FIGURE 11 | Levels of ADA vary between patients with and without
rheumatoid factor (RF) in prospective cohort. Significantly higher levels of ADA
were detected in samples (n = 89) from patients with RF compared to the
samples (n = 73) from those patients who were RF negative. The ADA levels
presented as median (red lines) and interquartile range (whiskers).
including the incomprehensive conclusions of test results with
very drug-sensitive ADA assays. Current recommendations
advise starting with a screening of drug level and then only
testing for ADA in samples with less sIFX than tolerated by
the drug sensitive ADA assays (with our in-house ELISA
corresponding to <0.2µg/mL) (28, 34). This is challenged by
introducing an ADA assay that is insensitive to drug level. This
assay enables reliable ADA testing at any time, not only in
trough, but also requires that a new drug level prompting ADA
testing is established. Moreover, while there are already existing
guidelines for suggested target trough concentrations for sIFX in
patients with inflammatory bowel disease (35), the optimal sIFX
level in rheumatic diseases is unknown. The aim of this study
was to estimate an optimal sIFX range, set a recommendation for
when to test for ADA using a drug-tolerant assay and to provide
a clinical threshold value for this assay using two large cohorts of
infliximab treated patients.
By correlating clinical data with sIFX levels and establishing a
suggested optimal range, we found that a substantial proportion
of patients were on a suboptimal treatment regimen in a cohort
of patients that had been treated for several years. Since sIFX
trough levels are highly variable between patients, the initial
screening of sIFX trough level is already able to give an indication
FIGURE 12 | Levels of ADA vary between RA patients with a different smoking
status in prospective cohort. Significantly higher levels of ADA were detected
in the samples (n = 84) from ever smokers compared to the samples (n = 63)
from patients who had never smoked. The ADA levels presented as median
(red lines) and interquartile range (whiskers).
of treatment efficacy. Collectively, our results from a range of
IFX treated diseases in this cohort suggest that a trough sIFX
concentration between 1 and 6µg/mL is possibly associated
with better treatment effect and therefore, a potential proxy for
an optimal sIFX level. The added value of identifying patients
with either too low or too high drug levels is evident, since
these two groups have different reasons for their sub-optimal
levels which need to be managed in different ways. As of
today, although there are several recommendations, there is no
consensus on the range of sIFX trough concentration at which
patients achieve an optimal therapeutic response. These ranges
can also vary depending on what drug, indication and assays
are used and therefore, would need to be established for each
method (25, 28, 36). As previous studies show, low trough levels
of sIFX predict disease activity in RA and as confirmed in this
study is most probably due to blocking of the therapeutic effect
by ADA (37). These patients might benefit from switching to
another TNFi alternative for which the patient has not developed
any resistance against. This is in line with the experience with
rituximab treatment, where patients developing ADA can regain
treatment effect when switching to another anti-CD20 drug (38).
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FIGURE 13 | Recommended infliximab treatment algorithm for RA based on the results of this study. With an algorithm starting with a measuring of the sIFX level at
14 weeks after treatment initiation, patients divided into four main categories. Group 1 and Group 2 consists of patients with either undetectable infliximab levels
(<0.2µg/mL) or low sub-therapeutic sIFX trough levels (<1µg/mL) and should therefore be tested for ADA with ELISA or a drug-tolerant assay (PandA), respectively.
For ADA positive patients, other treatment options should be considered depending on the ADA level and its relationship with the clinical threshold value. If the sample
is ADA positive with a RECL value >3, the patient should be switched to another treatment. If the ADA level is lower than 3 RECL one could continue treatment but
consider repeat testing for ADA again in the coming months to monitor ADA development with the quantitative PandA assay. Group 3 is within the optimal range of
sIFX level and no action is needed if the disease is in remission or demonstrating an acceptable response to treatment. If the disease is not in remission despite sIFX
being within optimal range, a drug with another mode of action might be needed. Group 4 include patients with a sIFX trough level that is higher than the normal
range (>6µg/mL). Lowering the dose should be considered if the patient responds well to infliximab, and other treatment options with another mode of action might
be considered for the patient who are not responding well and has active disease.
Patients with too high drug level were also not doing as well
as those within the range of 1–6µg/mL and therefore it is
sensible to analyze these as a separate group. Using the drug
tolerant PandA method, we could show that this is not ADA
bound in immune complexes. Therefore, the poor treatment
effect is likely attributed an initial primary treatment response,
and patients have been given a higher dose in attempt to improve
this. However, since the drug is not fully consumed before the
next infusion, in these patients, the TNF may not be the major
driver of disease severity and therefore, may benefit from a
therapeutic drug with another mode of action. Similar findings
are available for adalimumab treatment (36), where patients with
low drug level still had good effect with another TNFi whereas
those with a higher drug level did not. There are no biomarkers
available that can predict what mode of action the drug should
have to achieve optimal treatment response in an individual
patient. Indeed, a recent study by Berkhout et al. showed that
the level of circulating TNF-α during adalimumab treatment did
not predict clinical response in RA and thus cannot be used
as a biomarker for treatment discontinuation (39). In practice,
clinicians change intervals and dose without having the drug
level and ADA information, but this may be optimized with
the understanding of how to interpret the drug level and ADA
data (40).
One argument against drug level and ADA testing to monitor
treatment response in clinical practice is that treatment failure is
evident as disease break through. However, in the cross-sectional
cohort with >2 years of treatment, we observed that only two-
thirds of the patients, at any investigated time points, had the
suggested optimal drug concentration (1–6µg/mL), leaving 30%
of the patients with either too low or too high drug levels.
For the patients with too low levels (<1µg/mL), ADA was
detected in the majority of serum samples with a drug level
below 0.2µg/mL, meaning that they have been on treatment
for a long period without a biologically relevant effect of the
drug. ADA was also identified in samples with measurable drug
levels using the drug-tolerant assay, but rarely in those with a
drug level above 1µg/mL. Thus, by testing sIFX and ADA in
clinical practice, up to one-third of the patients might receive
a more optimal treatment. By using PandA for detection of
ADA bound in complex with the drug, we identified more ADA
positive cases. In addition, this method can be used if one needs
to know the ADA status right after infusion, for example to
determine if infusion reactions or serum sickness might be due
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to ADA (41, 42). When comparing the ADA positivity between
the two cohorts included in this study, it indeed shows that
to some extent ADA positive patients are identified clinically.
This is shown, as expected, by a lower frequency of ADA in the
cross-sectional cohort (34% of ADA positive samples compare to
23% in the prospective, with sIFX level >0.2µg/mL), indicating
that the ADA positive patients had already been switched to
another treatment due to lack of effect determined by clinical
outcome. However, a substantial proportion of patients still had
suboptimal sIFX level and clinically were not in remission. Thus,
measuring the drug level is of clinical value since it can help with
the dosing regimen. For example, large individual differences in
drug concentration in patients with multiple sclerosis treated
with the monoclonal antibody natalizumab has been shown
by van Kempen and colleagues were the majority had high
trough levels at the time of re-dosing (43). This could partly be
explained by that natalizumab is administered at a fixed dose
of 300mg every 4 weeks, not accounting for body weight or
pharmacokinetic differences. The authors therefore suggest that
the treatment regimen should adapt to a personalized approach
to allow efficient use of natalizumab (43).
We investigated the added value of using the bioassay iLite for
identification of neutralizing ADA and showed that 66% of the
samples were positive for neutralizing ADA. This is far less than
what was reported in a study published by Schie and colleagues,
which showed that the majority (>90%) of the ADA to infliximab
were neutralizing using a TNF competition assay (44). The
difference in the number of detected neutralizing samples could
be due to assay format, treatment duration at serum sampling,
and the small patient cohort size. There was a good correlation
between the neutralizing ADA and the PandA RECL values,
showing that the level of ADA is of most importance and
thus that PandA RECL values can be used as an indicator of
neutralizing capacity and clinical effect. Using this approach, it
is then most important to know at what level to set the clinical
threshold value for ADA. Here we provide an estimate of 3 RECL
with the PandA assay as the level of ADA that begins to be
detrimental for the therapeutic effect.
The correlation between the PandA assay and the ELISA ADA
assay was not perfect, with more discrepancies in the lower
levels of ADA positivity. Moreover, the ADA-ELISA is not a
quantitative assay and therefore if you want to set a clinical
threshold value, then alternativemore linearmethods are needed.
This shows the value of conducting pilot studies in real-life
settings to compare assays and to determine the assay specific
clinical threshold value before it is applied in the clinic. For the
samples with sIFX trough level below 0.2µg/mL, the ELISA have
a higher sensitivity than PandA and this is might be due to the
additional washing steps required in the PandA method.
The inverse correlation between drug level and ADA was
confirmed. However, five samples with a drug trough level below
0.2µg/mL that were identified as ADA negative with ELISA were
tested with PandA for potential drug/ADA immune complexes,
but only one sample showed low ADA reactivity, indicating
that other explanations for low drug levels need to be taken
into consideration (data not shown). Since infliximab is given
intravenously the compliance is controlled for and therefore,
could not be the issue here. It is possible that some patients
are highly efficient in metabolizing or consuming the drug and
studies of biomarkers associated with this trait might resolve
this issue.
The timing of the testing is essential. From the prospective
longitudinal cohort, we can conclude that the value of testing for
sIFX before the initiation period of shorter intervals is over, is
questionable. At week 14, the mean sIFX stabilizes, and around
half of the ADA positive patients could be identified already
here. However, although some of these patients were transiently
positive, none of these reached the suggested clinical threshold
value of 3 RECL. Some patients that later became ADA positive
in ELISA could have be detected as ADA positive with PandA
at earlier time points, when the sIFX levels were too high to give
reliable ADA test results with ELISA. Thus, if a first-tier screening
for sIFX is used, then testing at week 6, before the 3rd infusion
with a drug tolerant assay, is suggested to provide the most added
value to the clinical practice.
We identified three exceptional cases with high sIFX and
high ADA levels for which ADA would have been detected
with PandA already at the 2nd or 3rd infusion. Here, the sIFX
test would not have guided the decision to test for ADA. At
this time point there were no clinical parameters that would
have indicated ADA positivity, but all three cases eventually had
infusion reactions and secondary treatment failure. A patient
with previous infliximab treatment was included in the cohort
and this patient also had high ADA identified using the PandA
method, already at the 2nd infusion, which would indicate
that the three exceptional cases might also have had infliximab
treatment before. However, according to the patients files all three
were newly diagnosed and had not previously received TNFi
treatment prior the start of this study.
Taken together, an infliximab treatment algorithm for RA
using the assays included in this study has been be suggested
(Figure 13). For patients with low sub-therapeutic sIFX trough
levels and no detectable ADA, a dose escalation of infliximab
could be beneficial. Patients with therapeutic levels within the
recommended range for the chosen endpoint but still an active
disease are likely to have pharmacodynamic failure and may
benefit from switching to a drug with a different mechanism of
action. Samples with a serum trough drug level below 1µg/mL
(to include assay variation around 0.85µg/mL) would benefit
from being screened for ADA using the drug-tolerant assay in
order to discriminate whether discontinued treatment or dose
escalation should be implemented. Clinical assessment scores
would aid the evaluation of patients with a serum drug level above
6µg/mL (to include assay variation around 6µg/mL) to ascertain
if it could be beneficial to either lower the dose or switch to a drug
with a different mechanism of action.
There are some limitations to be mentioned in this study.
We have not considered other confounding factors that might
increase the risk for ADA. Tatarewicz et al. found that
rheumatoid factor, which are present in amajority of RA patients,
can interfere with the detection of monoclonal antibodies in
immunogenicity assays (45). This is particularly a problem when
using a sensitive immunoassay such as the PandA. Tatarewicz
and colleagues found that samples from RA patients had a higher
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baseline value of ADA reactivity than healthy subjects, thus the
RF could lead to a false positive signal in the immunoassay (45).
Here, we used untreated RA patient serum to set a disease specific
cut point, which was slightly higher than normal healthy serum.
However, one can question the clinical usefulness of such practice
since low positive ADA probably do not have any immediate
clinical relevance. Furthermore, the goal of the treatment is to
reduce inflammation and thus when this is achieved, the serum
profile may be more similar to normal healthy serum.
In conclusion, this cross-sectional and prospective study
examined whether measurement of sIFX trough level and ADA
testing correlated with treatment response and if adding a drug
tolerant assay provided additional clinically useful, accurate and
timely ADA results. Decisions of either switching treatment or
regulating the dose, need to be guided by evidence based optimal
drug levels and a clinical threshold value for ADA. The addition
of a drug tolerant assay PandA resolved cases with detectable
sIFX and identified ADA positivity earlier than the drug sensitive
assay. Even though test results of sIFX and ADA are both
heterogeneous and dynamic and thus difficult to interpret on
group level, on individual level and as a method to achieve
personalized treatment, these data are valuable.
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